Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | PSD | A5PKW4 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4832068 | 0.90 | CNR1 (0.49) | CNR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4832024 | 0.77 | CNR1 (0.51) | CNR1CYP3A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL4843834 | 0.71 | CNR1 (0.62) | CNR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4838891 | 0.70 | CNR1 (0.59) | CNR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4840707 | 0.69 | KDM1A (0.38) | CYP3A4CYP2C9PSDUSP2ALDH1A1 | |
| SCHEMBL4836643 | 0.69 | CNR1 (0.59) | CNR1CYP3A4CYP2C9CYP2C19ADORA2A | |
| SCHEMBL4832075 | 0.69 | CNR1 (0.55) | CNR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4838798 | 0.68 | CNR1 (0.69) | CNR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4839993 | 0.67 | CNR1 (0.57) | CNR1CYP3A4CYP2C9CYP2C19PSD | |
| SCHEMBL4835555 | 0.67 | CNR1 (0.55) | CNR1CYP3A4CYP2C9CYP2C19PSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452892-B2 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| WO-2006138734-A1 | TRIAZOLOPYRIMIDINE CANNABINOID RECEPTOR 1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287341-A1 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
| EP-1654229-A1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005009959-A1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287341-A1 | Triazolopyrimidine cannabinoid receptor 1 antagonists | CNR1, CNR2, GPR68 | CNR1 1/4885CYP3A4 537/4885CYP2C9 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.